IL178261A0 - Use of 5,10-methylene tetrahydrofolate for the treatment of cancer - Google Patents

Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Info

Publication number
IL178261A0
IL178261A0 IL178261A IL17826106A IL178261A0 IL 178261 A0 IL178261 A0 IL 178261A0 IL 178261 A IL178261 A IL 178261A IL 17826106 A IL17826106 A IL 17826106A IL 178261 A0 IL178261 A0 IL 178261A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
methylene tetrahydrofolate
tetrahydrofolate
methylene
Prior art date
Application number
IL178261A
Other languages
English (en)
Original Assignee
Adventrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adventrx Pharmaceuticals Inc filed Critical Adventrx Pharmaceuticals Inc
Publication of IL178261A0 publication Critical patent/IL178261A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL178261A 2004-04-02 2006-09-21 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer IL178261A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55888904P 2004-04-02 2004-04-02
US62547904P 2004-11-04 2004-11-04
US65874505P 2005-03-04 2005-03-04
PCT/US2005/011046 WO2005097086A2 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL178261A0 true IL178261A0 (en) 2006-12-31

Family

ID=35125596

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178261A IL178261A0 (en) 2004-04-02 2006-09-21 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Country Status (7)

Country Link
US (1) US20070280944A1 (enExample)
EP (1) EP1740182A2 (enExample)
JP (1) JP2007531728A (enExample)
AU (1) AU2005231436A1 (enExample)
CA (1) CA2561952A1 (enExample)
IL (1) IL178261A0 (enExample)
WO (1) WO2005097086A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152228A2 (en) * 2008-06-10 2009-12-17 Yale University Use of the combination of phy906 and a tyrosine kinase inhibitor as a cancer treatment regimen
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
WO2008109349A1 (en) * 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
CA2738755C (en) * 2008-09-26 2018-11-06 Universite D'angers Individual 5-fluorouracile dose optimization in folfiri treatment
CA2738753C (en) * 2008-09-26 2018-11-06 Universite D'angers Individual 5-fluorouracile dose optimization in folfox treatment
EP2617421A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP3446704A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3305318A1 (en) * 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
CN110430896A (zh) 2017-02-14 2019-11-08 伊索弗尔医药公司 用于增加血浆2′-脱氧尿苷(dUrd)和胸苷酸合成酶抑制的方法
CN110573178A (zh) * 2018-01-05 2019-12-13 伊索弗尔医药公司 治疗结直肠癌和转移性结直肠癌的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy

Also Published As

Publication number Publication date
WO2005097086A2 (en) 2005-10-20
WO2005097086A3 (en) 2006-05-18
US20070280944A1 (en) 2007-12-06
EP1740182A2 (en) 2007-01-10
JP2007531728A (ja) 2007-11-08
AU2005231436A1 (en) 2005-10-20
CA2561952A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL206984A0 (en) Analoges of benzoquinone-containing ansamycins for the treatment of cancer
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
IL164599A0 (en) Combination therapy for the treatment of cancer
SI1673352T1 (sl) Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravila
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL164896A0 (en) Immunoconjugates for the treatment of tumours
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
IL180256A0 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
GB0428187D0 (en) Cancer treatment
ZA200709542B (en) Combination therapy in the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
PL1881830T3 (pl) Pochodne 4-fenylo-5-okso-1,4,5,6,7,8-heksahydrochinoliny do leczenia niepłodności
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0517387D0 (en) Combinations for the treatment of cancer
IL175689A0 (en) Enoxaparin for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer